In metastatic renal cell carcinoma (mRCC) patients, cardiac metastases are a rare and often a post-mortem finding. Clinical manifestations of cardiac metastases have a late onset and include pericardial effusions, heart failure and embolic phenomena. Treatment of cardiac metastasis is not yet standardized, and few data are available about the efficacy of TKI on treatment of cardiac metastases in mRCC patients. In this report, we describe the case of a 66-year-old male who presented with mRCC with lung and cardiac metastases treated with cabozantinib, a multikinase inhibitor that was administered in second line after disease progression with sunitinib. To date, there are no data about the safety and efficacy of cabozantinib in mRCC with cardiac metastasis. In a real word analysis, cabozantinib demonstrated to be associated to a modest risk of developing left ventricular heart failure. It is unknown if this risk is higher in mRCC population with cardiac metastases. We report the first evidence of efficacy and safety of cabozantinib in cardiac mRCC patients, probably due to its specific inhibition of several molecular intracellular pathways. Additional molecular and clinical studies are needed before well tolerated and efficacy of cabozantinib treatment for these patients can be fully understood.

Response to cabozantinib in renal cell carcinoma with cardiac metastases / Stellato, M; Cursano, Mc; Citarella, F; Pantano, F; Russano, M; Dell'Aquila, E; Vincenzi, B; Tonini, G; Santini, D.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 31:3(2020), pp. 314-317. [10.1097/CAD.0000000000000889]

Response to cabozantinib in renal cell carcinoma with cardiac metastases

Santini D.
2020

Abstract

In metastatic renal cell carcinoma (mRCC) patients, cardiac metastases are a rare and often a post-mortem finding. Clinical manifestations of cardiac metastases have a late onset and include pericardial effusions, heart failure and embolic phenomena. Treatment of cardiac metastasis is not yet standardized, and few data are available about the efficacy of TKI on treatment of cardiac metastases in mRCC patients. In this report, we describe the case of a 66-year-old male who presented with mRCC with lung and cardiac metastases treated with cabozantinib, a multikinase inhibitor that was administered in second line after disease progression with sunitinib. To date, there are no data about the safety and efficacy of cabozantinib in mRCC with cardiac metastasis. In a real word analysis, cabozantinib demonstrated to be associated to a modest risk of developing left ventricular heart failure. It is unknown if this risk is higher in mRCC population with cardiac metastases. We report the first evidence of efficacy and safety of cabozantinib in cardiac mRCC patients, probably due to its specific inhibition of several molecular intracellular pathways. Additional molecular and clinical studies are needed before well tolerated and efficacy of cabozantinib treatment for these patients can be fully understood.
2020
cabozantinib; cardiac metastases; inferior cava vein thrombosis; renal cell carcinoma; aged; anilides; carcinoma; renal cell; heart neoplasms: humans; kidney neoplasms; male; pyridines
01 Pubblicazione su rivista::01i Case report
Response to cabozantinib in renal cell carcinoma with cardiac metastases / Stellato, M; Cursano, Mc; Citarella, F; Pantano, F; Russano, M; Dell'Aquila, E; Vincenzi, B; Tonini, G; Santini, D.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 31:3(2020), pp. 314-317. [10.1097/CAD.0000000000000889]
File allegati a questo prodotto
File Dimensione Formato  
Stellato_Response_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.62 MB
Formato Adobe PDF
2.62 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1641981
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
social impact